Timothy Pellegrin
Psychiatric/Mental Health · Houma, LANPI 1134160815
Payments from drug & device makers
Across 800 payments — averaging $262.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$123K
- AbbVie$80K
- Teva Pharmaceuticals USA, Inc.$1K
- Alkermes, Inc.$977
- Supernus Pharmaceuticals, Inc.$839
- Vanda Pharmaceuticals Inc.$742
- plus $4K from 18 others
What the payments were for
- Consulting fees$3,7452%
- Speaking & faculty fees$176,27084%
- Travel & lodging$15,8218%
- Food & beverage$13,6487%
- Education$3170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 294 | $122,825 |
| AbbVie(2 entities) | 173 | $79,600 |
| Teva Pharmaceuticals USA, Inc. | 43 | $1,121 |
| Alkermes, Inc. | 47 | $977 |
| Supernus Pharmaceuticals, Inc. | 25 | $839 |
| Vanda Pharmaceuticals Inc. | 28 | $742 |
| Otsuka America Pharmaceutical, Inc. | 34 | $686 |
| Corium, LLC | 35 | $537 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $440 |
| Axsome Therapeutics, Inc. | 22 | $389 |
| Ironshore Pharmaceuticals Inc. | 19 | $327 |
| Johnson & Johnson | 5 | $312 |
| Neurocrine Biosciences, Inc. | 10 | $266 |
| Sunovion Pharmaceuticals Inc. | 13 | $219 |
| Lundbeck LLC | 10 | $181 |
| Collegium Pharmaceutical, Inc. | 4 | $73 |
| Tris Pharma Inc | 4 | $67 |
| Ardelyx, Inc. | 2 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Merck | 2 | $28 |
| Abbott | 1 | $25 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| Indivior Inc. | 1 | $17 |
| Eisai Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$209,801 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 127 | $213,419 |
| Austedo XrDeutetrabenazine | 16 | $204,629 |
| CaplytaLumateperone Tosylate | 43 | $89,761 |
| RexultiBrexpiprazole | 51 | $75,552 |
| LybalviOlanzapine/Samidorphan Malate | 32 | $54,127 |
| AuvelityDextromethorphan Hbr/Bupropion | 38 | $41,736 |
| Invega SustennaPaliperidone Palmitate | 13 | $39,880 |
| BelsomraSuvorexant | 45 | $20,853 |
| Seroquel XrQuetiapine Fumarate | 13 | $16,691 |
| TrintellixVortioxetine Hydrobromide | 13 | $10,450 |
| MydayisDextroamphetamine/Amphetamine | 15 | $4,926 |
| Bupropion XlBupropion Hcl | 170 | $3,764 |
| DayvigoLemborexant | 11 | $3,720 |
| Atomoxetine Hcl | 15 | $3,418 |
| Quetiapine Fumarate | 123 | $3,025 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $79,600 | $213,419127 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,121 | $204,62916 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $122,825 | $89,76143 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $686 | $75,55251 claims |
| Alkermes, Inc.Lybalvi | $977 | $54,12732 claims |
| Axsome Therapeutics, Inc.Auvelity | $389 | $41,73638 claims |
| Johnson & JohnsonInvega Sustenna | $312 | $39,88013 claims |
| MerckBelsomra | $28 | $20,85345 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $440 | $10,45013 claims |
| Eisai Inc.Dayvigo | $11 | $3,72011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Houma
- Amanda EymardHouma$617K
- Harry BrownHouma$9K
- Amy LacoutureBaton Rouge$663K
- Amber LittlefieldBroussard$225K
- Melissa GuilbeauLafayette$122K
- Kimberly ForcinelShreveport$92K
- Sattaria DilksLake Charles$57K
- Joe TaylorHammond$38K
- Lecy AlbaradoScott$34K
- Michelle DyerLake Charles$33K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.